Novartis Reveals Two Deaths Related to SMA Drug Zolgensma
By Mark Terry,
BioSpace
| 08. 12. 2022
Novartis’ gene therapy for spinal muscular atrophy (SMA) has had a complicated history, of which there is a new chapter. Two patients receiving the therapy have died from acute liver failure, the company reported Thursday.
“While this is important safety information, it is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile of Zolgensma, which to date has been used to treat more than 2,300 patients worldwide across clinical trials, managed access programs and in the commercial setting,” Novartis stated in a press release.
Novartis reported that the children developed acute liver failure about five to six weeks after receiving Zolgensma and about 1-10 days after initiation of corticosteroid taper. The corticosteroids are used to help manage risk from the therapy. The cases were in Russia and Kazakhstan.
The company indicated it has notified regulators in all countries where the therapy is approved and will inform healthcare providers where it is allowed. The company also plans to update the Zolgensma label to include mention of the deaths.
SMA is...
Related Articles
By Elizabeth Dwoskin and Zoeann Murphy, The Washington Post | 10.01.2025
MEXICO CITY — When she walked into an IVF clinic in June, Alin Quintana knew it would be the last time she would try to conceive a child. She had prepared herself spiritually and mentally for the visit: She had traveled to a nearby...
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Jessica Mouzo, El País | 10.03.2025
DNA is the molecule of life: this double-helix structure, present in every cell in the body and organized into fragments called genes, stores the instructions for making organisms function. It is a highly precise biological machine, but sometimes it breaks...
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
